SCHEMBL15935396

SCHEMBL15935396

Cc1ccn(-c2ccnc(C)n2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.61
RAB9A P51151 2/20 0.61
NPC1 O15118 1/20 0.61
ATM Q13315 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
TDO2 P48775 1/20 0.37
HTT P42858 1/20 0.37
SORD Q00796 2/20 0.33
LMNA P02545 1/20 0.33
CYP17A1 P05093 1/20 0.33
ADORA2A P29274 2/20 0.32
GRM4 Q14833 2/20 0.32
NOS1 P29475 1/20 0.32
KCNN3 Q9UGI6 2/20 0.31
PIK3CA P42336 1/20 0.31
MTOR P42345 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19100786 0.82 MAPT (0.58) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15923959 0.82 NPC1 (0.41) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935402 0.81 MAPT (0.56) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935018 0.80 MAPT (0.54) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935025 0.78 MAPT (0.53) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935017 0.78 MAPT (0.53) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL197523 0.76 MAPT (1.00) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL23697527 0.74 ALDH1A1 (0.48) MAPTRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL11983495 0.74 RAB9A (0.52) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15886672 0.73 RAB9A (0.85) MAPTRAB9ANPC1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2934538-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2021-03-31 EP disclosed
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 MAPT 4751/4885RAB9A 556/4885NPC1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.